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MELAMPOMAGNOLIDE B DERIVATIVES AS 
ANTILEUKEMIC AND CYTOTOXIC AGENTS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the bene?t of US. provisional 
application Ser. No. 61/405,978 ?led on Oct. 22, 2010, the 
entire contents of which are incorporated herein by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with government support under 
grant number W81XWH-07-1-0601, awarded by the United 
States Department of Defense; and under grant number 
C024964, awarded by the New York State Stem Cell Foun 
dation. The government has certain rights in the invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
Melampomagnolide B (3) is disclosed as a new antileuke 
mic sesquiterpene. A biotin-conjugated derivative (4) of 
melampomagnolide B was prepared to elucidate its mecha 
nism of action. A study of the biochemical interactions of the 
biotin probe suggests that melampomagnolide B derives its 
remarkable selectivity for leukemic cells over normal 
hematopoietic cells from its unique ability to exploit bio 
chemical differences between the two cell types. Prodrugs of 
Melampomagnolide B are disclosed. 
2. Description of the Related Art 
The past several years have seen a surge of interest in the 
anticancer properties of sesquiterpene lactones. A germacre 
nolide, parthenolide (PTL, 1) has been noted for its remark 
able antileukemic properties. Skalska et al. PLoS ONE, 2009, 
4, e81 15. Initial efforts pertaining to the biomechanistic study 
of parthenolide and its analogs revealed that they seem to 
promote apoptosis by inhibiting the activity of the NF-kB 
transcription factor complex, and thereby down-regulating 
anti-apoptotic genes under NF-kB control. Bork et al. FEBS 
Len. 1997, 402, 85; Wen, J. Biol. Chem, 2002, 277, 38954; 
Hehner et al., J. Biol. Chem. 1998, 273, 1288; Sweeney et al., 
Clin. Cancer Res., 2004, 10, 5501 ;Yip-Schneider et al., Mol. 
Cancer. Then, 2005, 4, 587; Nozaki et al., Oncogene, 2001, 
20, 2178. Nuclear factor kB (NF-kB) is a transcriptional 
regulator that plays a central part in responses to in?amma 
tory signaling. 
Parthenolide (PTL) 
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-continued 
HOZC 
IICOZH, O 
Dimethylaminoparthenolide (DMAPT) furnarate; LC—l 
Melampomagnolide B (MMB) 
Parthenolide induces robust apoptosis of primary acute 
myeloid leukemic (AML) cells. Guzman et al., Blood, 2005, 
105, 4163; Guzman and Jordan, Exp. Opin. Biol. Ther., 2005, 
5, 1147. In particular, parthenolide causes cell death in AML 
stem and progenitor cells in vitro, with minimal toxicity 
towards normal hematopoietic cells. The apoptosis induced 
by parthenolide is not solely due to NF-kappaB inhibition, but 
rather arises from a broad set of biological responses, which 
likely include activation of p53 and an increase in reactive 
oxygen species. Parthenolide has also been the source of 
several novel antileukemic compounds arising from our pro 
gram over the past decade. For example, parthenolide analogs 
were prepared by adding amines to the exocyclic ole?n of the 
enone function of 1, thereby rendering the resulting com 
pounds water-soluble. Neelakantan et al., Bioorg. Med. 
Chem. LeZZ., 2009, 19, 4346; Nasim and Crooks, Bioorg. Med. 
Chem. Lell., 2008, 18, 3870. Such adducts showed retention 
of antileukemic properties of parthenolide; in particular, the 
dimethylamine-adduct of parthenolide (DMAPT, LC-1, 2), 
which has progressed to phase-I clinical trials in the United 
Kingdom for the treatment of AML, ALL and CLL. Neela 
kantan et al., 2009. 
Unfortunately, DMAPT has a relatively short in vivo half 
life (approximately two hours) which may limit its activity. 
Moreover, the design of this molecule does not readily afford 
opportunities to develop tissue-targeting strategies due to 
stability problems associated with drug formulation. This is 
related to the ability of the drug to undergo reverse Michael 
deamination reactions to generate parthenolide. Thus, there is 
a need to both improve the biological activity of PTL and 
create novel pharmacological agents with drug-like charac 
teristics that can be formulated as oral dosage forms. 
One PTL analog that was synthesized via selenium oxide 
oxidation was a C10 hydroxymethyl derivative. Notably, 
hydroxylation of the C10 methyl group of PTL resulted in the 
concomitant conversion of the geometry of the C9-C10 
double bond from trans to cis. The resulting product, a 
hydroxymethyl 1(10)-cis-parthenolide analog, has previ 
ously been reported as melampomagnolide B (MMB). 
Melampomagnolide B (MMB, 3) is a melampolide originally 
isolated from Magnolia grandi?ora. El-Feraly, Phylochem 
islry, 1984, 23, (10); 2372-2374. 
It is herein disclosed that melampomagnolide B (MMB, 3) 
has been identi?ed as a new antileukemic sesquiterpene with 
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properties similar to parthenolide (PTL, 1). Further, as a 
functionalized analog of PTL, the MMB molecule allows the 
synthesis of conjugated analogs that retainbiological activity. 
SUMMARY OF THE INVENTION 
Melampomagnolide B is disclosed as a neW antileukemic 
sesquiterpene. A biotin-conjugated derivative of melampo 
magnolide B was prepared to elucidate its mechanism of 
action. Prodrugs of Melampomagnolide B are disclosed. 
The disclosure provides a compound of the formula (I): 
0 
wherein: R is selected from iP(O)(OR1)(OR2); 4CH20P 
(O)(OR1)(OR2); iC(O)(CR3R4)nX; iCH20C(O) 
(CR3R4)n X; iC(O)O(CR3R4)nX or %(O)(CH2)MC(O) 
NH(CR3 , R4)nX; R1, R2 are independently selected from H; a 
pharmaceutically acceptable cation; or optionally substituted 
C1-C12alkyl, alkenyl, alkynyl, heterocycloalkyl, heteroaryl, 
cycloalkyl, aryl; R3, R4 are independently selected from H, 
NR5R6, ORl, SR1, S(O)Rl, SOle, or optionally substituted 
C1-C12alkyl, alkenyl, alkynyl, heterocycloalkyl, heteroaryl, 
cycloalkyl, aryl; R5, R6 are independently selected from H; or 
optionally substituted C1-C12alkyl, alkenyl, alkynyl, hetero 
cycloalkyl, heteroaryl, cycloalkyl, aryl; 4C02C1-C12alkyl, 
CO2alkenyl, COZalkynyl, COzheterocycloalkyl, 
COzheteroaryl, COchcloalkyl, COZaryl; C1-C12alkylamino 
or R5 and R6 optionally together With the nitrogen atom form 
an optionally substituted 5-12 membered ring, said ring 
optionally comprising 1 or more heteroatoms; X is selected 
from H, NR5R6, NC(O)R1; NC(O)OR1; ORl, SR1, halo, tri 
?uoromethyl, or optionally substituted C1-C12alkyl, alkenyl, 
alkynyl, heterocycloalkyl, heteroaryl, cycloalkyl, aryl; n is 
0-12; m is l-2; or a pharmaceutically acceptable salt, ester or 
prodrug thereof. 
In one aspect, R is selected from iP(O)(OR')(OR2) or 
iCH2OP(O)(ORl)(OR2). In another aspect, R1, R2 are inde 
pendently selected from H, Na, or optionally substituted 
C l-C6 alkyl. In certain speci?c aspects, R is 
20 
|| 2m+ 
P |\O_ 
O. 
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In one aspect, R is iC(O)(CR3R4)nX. In another aspect, X 
is NR5R6, ORl, or SR1. 
In speci?c aspects, R is selected from 
O 
NH; 
Gly 
2 
3 
O 
NH; 
[5—Ala. 
4 
5 
6 
7 
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-continued 
In another aspect, R is 4CH20C(O)(CR3R4)MX, and X is 
NR5R6. In a speci?c aspect R is 
EAOIVNHZ 
O 
O 1 
- Of 
0 
$0M NHZ. 
In another aspect, R is 4C(O)O(CR3R4)MX, Wherein X is 
NR5R6. In a speci?c aspect, R is 
In another aspect, R is or 4C(O)(CH2)MC(O)NH(CR3R4) 
"X, Wherein X is NR5R6. 
ll 
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In a speci?c aspect, R is selected from 
H 
N M WNHZ 
O O 
22n:l 
23n:2 
§ WN 
O O 
24n:l 
25n:2 
§ WN 
O O 
26n:l 
27n:2 
§ 
WN/W 
O O K/O 
28n:l 
29n:2 
(i H N / N \/ / 302—pyr 
313—pyr 
O O or 324—pyr. 
In one aspect, R5 and R6 together With N form an optionally 
substituted ring. In one speci?c aspect, the ring is a monocy 
clic, bicyclic or tricyclic alkyl or aryl ring system, said ring 
system optionally substituted and optionally comprising one 
or more heteroatoms or a group selected from 4COi, 
iSOi, iSOzi, and iPOi. In another speci?c aspect, 
R1 and R2 are i(CH2)aiYi(CH2)bi; Where Y is a het 
eroatom or a group selected from iCOi, iSOi, 
iSOZi and iPOi; a is an integer 0 to 5; b is an integer 0 
to 5; the sum of a and b being 0 to 5; and together With N form 
an optionally substituted ring, said ring optionally fused to a 
cycloalkyl or aryl group to form a bicyclic or tricyclic ring 
system, said system optionally substituted and optionally 
comprising one or more heteroatoms. 
In another aspect, Wherein X is NRSR6 the compound a 
pharmaceutically acceptable salt selected from hydrochlo 
ride, maleate, fumarate, or mesylate. 
US 8,884,027 B2 
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In another aspect, the disclosure provides a compound 
selected from 
NHFmo 0 
of 
In one embodiment, the disclosure provides a pharmaceu 
tical composition comprising a compound of formula (I) or a 
pharmaceutically acceptable salt thereof; in combination 
with a pharmaceutically effective diluent or carrier. 
In another embodiment, the disclosure provides a method 
of inhibiting cancer cell growth, comprising administering to 
a mammal a?licted with cancer, an amount of a compound of 
formula (I) effective to inhibit the growth of said cancer cells. 
In one aspect, the disclosure provides a method of inhibiting 
cancer cell growth comprising contacting said cancer cell in 
vitro or in vivo with an amount of a compound of formula (I) 
effective to inhibit the growth of said cancer cell. 
In another aspect, the disclosure provides a method of 
treating an aberrant in?ammatory condition, comprising 
administering to a mammal in need thereof, an amount of a 
compound of formula (I) effective to reduce, prevent or con 
trol said condition. In one aspect, the aberrant in?ammatory 
condition is an autoimmune disorder, said method compris 
ing administering to a mammal an amount of a compound of 
formula (I) effective to reduce, prevent or control said autoim 
mune disorder. 
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In certain aspects, the disclosure provides a compound of 
formula (I): 
(I) 
wherein R is a group that is cleaved to a hydroxy group under 
physiological conditions during or after administration to a 
mammalian patient, thereby yielding Melampomagnolide B; 
wherein R is selected from iP(O)(OR1)(OR2); iCHZOP 
(O)(OR1)(OR2); iC(O)(CR3R4)nX; iCHZOC(O) 
(CR3R4)n X; iC(O)O(CR3R4)nX or iC(O)(CH2)mC(O) 
NH(CR3R4)nX; R1, R2 are independently selected from H; a 
pharmaceutically acceptable cation; or optionally substituted 
C1-C12alkyl, alkenyl, alkynyl, heterocycloalkyl, heteroaryl, 
cycloalkyl, aryl; R3, R4 are independently selected from H, 
NR5R6, ORl, SR1, S(O)Rl, SOle, or optionally substituted 
C1-C12alkyl, alkenyl, alkynyl, heterocycloalkyl, heteroaryl, 
cycloalkyl, aryl; R5 , R6 are independently selected from H; or 
optionally substituted C1-C12alkyl, alkenyl, alkynyl, hetero 
cycloalkyl, heteroaryl, cycloalkyl, aryl; 4COZC1-Cl 2alkyl, 
COZalkenyl, COZalkynyl, COZheterocycloalkyl, 
COzheteroaryl, COchcloalkyl, COZaryl; C1-C12alkylamino 
or R5 and R6 optionally together with the nitrogen atom form 
an optionally substituted 5-12 membered ring, said ring 
optionally comprising 1 or more heteroatoms; X is selected 
from H, NR5R6, OR % SR % halo, tri?uoromethyl, or option 
ally substituted C1-C12alkyl, alkenyl, alkynyl, heterocy 
cloalkyl, heteroaryl, cycloalkyl, aryl; n is 0-6; m is 1-2; or 
a pharmaceutically acceptable salt, ester or prodrug thereof. 
In another embodiment, the disclosure provides a method 
of drug delivery comprising administering to a mammal, an 
amount of a compound of formula (I): 
(I) 
wherein R is a group that is cleaved to a hydroxy group under 
physiological conditions during or after administration to a 
mammalian patient, thereby yielding Melampomagnolide B; 
wherein the substituents are as described above. 
In another embodiment, the disclosure provides a method 
of treating bone marrow in human bone marrow transplant 
treatment of leukemia, the method comprising treating bone 
marrow with a compound of claim 1 prior to reintroduction of 
bone marrow to patient. In another embodiment, the disclo 
sure provides a method of treating a patient having chronic or 
acute myeloid leukemia (CML/AML) or acute lymphoblastic 
US 8,884,027 B2 
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leukemia (ALL), comprising administering to the patient, an 
effective amount of a compound of formula (I). 
In a further embodiment, the disclosure provides a method 
of treating a patient having chronic or acute myeloid leukemia 
(CML/AML) or acute lymphoblastic leukemia (ALL), com 
prising administering to the patient, an effective amount of 
melampomagnolide B. 
In another embodiment, the disclosure provides a method 
of inhibiting angiogenesis in a patient in need thereof, com 
prising administering to the patient, an effective amount of a 
compound of formula (I). 
In another embodiment the disclosure provides a method 
of inhibiting angiogenesis in a patient in need thereof, com 
prising administering to the patient, an effective amount of a 
compound of melampomagnolide B 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows a route of synthesis of melampomagnolide B 
(MMB, 3) from parthenolide (PTL, l), and conjugation of 
biotin to 3. 
FIG. 2 shows viability of primary AML specimens when 
treated for 18 hours with either PTL, l, or MMB, 3, compared 
to control, untreated cells. 
FIG. 3 shows biological activities of 4 compared to l and 3. 
FIG. 3A shows immunoblot of phosphorylatedp65 subunit of 
the NF-kB complex and actin. FIGS. 3B-D shows viability of 
primary leukemia cells after overnight culture at varying con 
centrations. 
FIG. 4 shows binding of targets of 4 in NBM and AML 
samples in an immunoblot analysis using a streptavidin 
probe. The asterisk* marks a non- speci?c band recognized by 
SA-HRP probe. Whole cell lysates from normal bone marrow 
(NBM) in lane 2 is shown in comparison to acute myeloid 
leukemia (AML) cells in lane 3. An identical protein/com 
pound 4 ratio was used for NBM and AML preparations. 
FIG. 5 shows Western blot of primary leukemia cells that 
were pretreated for 2 h with compound 1 (lanes 2, 5) or biotin 
control (b.c.) (lanes 3,6), prior to a 4 h incubation with com 
pound 4. Cells were then lysed and immuno-precipitated by 
streptavidin beads. Pulldown products were analyzed by 
immunoblot to identify speci?c proteins. One product iden 
ti?ed was IKK-B, the known target of compound 1; also the 
NF-kB p65 subunit was identi?ed as a direct target in the 
pull-down. Preincubation with compound 1 potently reduced 
binding of IKK-B or p65 to compound 4 (lane 5), indicating 
such binding between IKK-B or p65 and compound 4 is 
through the same mechanism between IKK-B or p65 and 
compound 1. 
FIG. 6 shows another Western blot analysis of AML cells 
using compound 4, with and without treatment with com 
pound 1. Primary AML cells were treated with PTL-biotin for 
6 hours followed by lysis and biochemical pull-downs using 
streptavidin coated agarose beads. Controls include cells 
incubated with biotin alone, or preincubated with native PTL 
prior to the addition of PTL-biotin. (i.e. competitive binding 
studies). Lysates were analyzed by Western blot (WB) for the 
presence of IKK or thioredoxin. (TXN). Lanes l-3 labeled 
“input” represent whole cell lysates for each condition. Lanes 
4-6, labeled “pull-down” are the material bound to streptavi 
din beads. No pull down is observed with biotin alone (lane 
4). Both proteins are bound by PTL-biotin (lane 5). Pre 
incubation with PTL competes the PTL-biotin interaction 
(lane 6). 
FIG. 7 shows ef?ciency of gene transfer for primary AML 
specimens. Green ?uorescent protein (GFP) has been widely 
used as a lineage marker for mammalian cells. The use of 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
10 
?uorescent proteins allows cells to be tracked during manipu 
lation. Primary AML cells exposed to a concentrated lentivi 
rus encoding GFP for 6 hours. Analysis 8 hours later (A) and 
at 7 days (B) post-infection. Primary AML specimens (C) 
were infected with lentivirus encoding GFP and analyzed 
after overnight culture. (D) Western blot showing ef?cacy of 
lentiviral expression of shRNA targeted to the Nrf2 mRNA. 
FIG. 8 shows derivatives of MMB. Various ester, ether, 
carbamate, carbonate and phosphate MMB derivatives are 
proposed to act as water-soluble, orally bioavailable MMB 
prodrugs. 
FIG. 9A shows conversion of prodrug-to-parent drug 
involves a chemical cleavage at the self-cleavable spacer 
through a intramolecular cyclization-elimination reaction via 
imide formation under physiological conditions. 
FIG. 9B shows synthesis of prodrugs 1-13 from FIG. 8. 
Prodrugs l -10 can be synthesized by Steglich esteri?cation of 
MMB with an appropriate amino group protected AA to 
afford compound 34, followed by deprotection of the amino 
group. Reaction of MMB with an appropriate Boc-AA chlo 
romethyl ester 35 will afford compound 36, which upon 
deprotection will furnish prodrugs 11-13. 
FIG. 10 A shows synthesis ofprodrugs 14-19 from FIG. 8. 
Carbamate prodrugs 14-17 and carbonate prodrugs l8 and 19 
can be prepared from the substitution reaction between 
mono-Boc protected diamine or N-Boc aminopropanol (38) 
and 4-nitrophenyl MMB carbonate (37), followed by depro 
tection. Compound 37 can be prepared by reacting MMB 
with 4-phenyl chloroformate. 
FIG. 10B shows synthesis ofprodrugs 20 and 21 from FIG. 
8. Phosphate prodrug 20 can be synthesized by standard 
conditions using the phosphoramidite method. Deprotection 
of the phosphate triester (39) can be accomplished by treat 
ment with TMSBr. The oxymethyl phosphate prodrug 21 can 
be synthesized by initial formation of a methylthiomethyl 
ether (40) from MMB, followed by reaction of compound 40 
with phosphoric acid in the presence of NCl, and then treat 
ment with Na2CO3. 
FIG. 11 shows synthesis of prodrugs 22-32 from FIG. 8. 
Prodrugs 22-32 can be synthesized by initial treatment of 
MMB with succinic anhydride in the presence of dicyclo 
hexylamine (DCHA) to form hemisuccinate 41, followed by 
coupling of 41 with amine 42 or 43 utilizing the EDCI-HOBt 
coupling method, and deprotection (for 22 and 23). 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
De?nitions 
As used herein, the following de?nitions shall apply unless 
otherwise indicated. 
The phrase “optionally substituted” is used interchange 
ably with the phrase “substituted or unsubstituted.” Unless 
otherwise indicated, an optionally substituted group may 
have a substituent at each substitutable position of the group, 
and each substitution is independent of any other. Also, com 
binations of substituents or variables are permissible only if 
such combinations result in stable compounds. In addition, 
unless otherwise indicated, functional group radicals are 
independently selected. Where “optionally substituted” 
modi?es a series of groups separated by commas (e.g., 
“optionally substituted A, B or C”; or “A, B or C optionally 
substituted with”), it is intended that each of the groups (e. g., 
A, B and C) is optionally substituted. 
The term “aliphatic” or “aliphatic group” as used herein 
means a straight-chain or branched C 1_l 2 hydrocarbon chain 
US 8,884,027 B2 
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that is completely saturated (alkyl) or that contains one or 
more units of unsaturation (alkenyl, alkynyl), or a monocyclic 
C3_8 hydrocarbon or bicyclic C8_12 hydrocarbon that is com 
pletely saturated or that contains one or more units of unsat 
uration, but which is not aromatic (also referred to herein as 
“carbocycle” or “cycloalkyl”), that has a single point of 
attachment to the rest of the molecule wherein any individual 
ring in said bicyclic ring system has 3-7 members. For 
example, suitable aliphatic groups include, but are not limited 
to, linear or branched or alkyl, alkenyl, alkynyl groups and 
hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl 
or (cycloalkyl)alkenyl. 
The terms “alkyl,” “alkoxy,” “hydroxyalkyl,” “alkoxy 
alkyl” and “alkoxycarbonyl,” used alone or as part of a larger 
moiety include both straight and branched chains containing 
one to eighteen carbons; one to twelve carbon atoms; one to 
six carbons or one to four carbons. The terms “alkenyl” and 
“alkynyl” used alone or as part of a larger moiety shall include 
both straight and branched chains containing two to twelve 
carbon atoms. 
The terms “haloalkyl,” “haloalkenyl” and “haloalkoxy” 
means alkyl, alkenyl or alkoxy, as the case may be, substituted 
with one or more halogen atoms. The term “halogen” or 
“halo” means F, Cl, Br or I. 
The term “heteroatom” means nitrogen, oxygen, or sulfur 
and includes any oxidized form of nitrogen and sulfur, and the 
quaternized form of any basic nitrogen. Heteroatom further 
includes Se, Si and P. 
The term “aryl” used alone or in combination with other 
terms, refers to monocyclic, bicyclic or tricyclic carbocyclic 
ring systems having a total of ?ve to fourteen ring members, 
wherein at least one ring in the system is aromatic and 
wherein each ring in the system contains 3 to 8 ring members. 
The term “aryl” may be used interchangeably with the term 
“aryl ring”. The term “aralkyl” refers to an alkyl group sub 
stituted by an aryl. The term “aralkoxy” refers to an alkoxy 
group substituted by an aryl. 
The term “heterocycloalkyl,” “heterocycle,” “heterocy 
clyl” or “heterocyclic” as used herein means monocyclic, 
bicyclic or tricyclic ring systems having ?ve to fourteen ring 
members in which one or more ring members is a heteroatom, 
or C:O, wherein each ring in the system contains 3 to 7 ring 
members and is non-aromatic. Examples of heterocycloalkyl 
include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tria 
Zolidinyl, l,3-dioxolanyl, piperidinyl, piperaZinyl, morpholi 
nyl, dioxanyl, hexahydropyrimidinyl; each optionally substi 
tuted with H, C l-C6 alkyl, cycloalkyl, hydroxy, amino, halo or 
tri?uoromethyl groups. 
The term “heteroaryl,” used alone or in combination with 
other terms, refers to monocyclic, bicyclic and tricyclic ring 
systems having a total of ?ve to fourteen ring members, and 
wherein: l) at least one ring in the system is aromatic; 2) at 
least one ring in the system contains one or more heteroatoms; 
and 3) each ring in the system contains 3 to 7 ring members. 
The term “heteroaryl” may be used interchangeably with the 
term “heteroaryl ring” or the term “heteroaromatic”. 
Examples of heteroaryl rings include 2-furanyl, 3-furanyl, 
2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 
4-isoxazolyl, isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-ox 
azolyl, 4-oxazolyl, 5-oxazolyl, l-pyrrolyl, 2-pyrrolyl, 3-pyr 
rolyl, l-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-pyridyl, 3-py 
ridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 
3-pyridaZinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetra 
zolyl, 2-triazolyl, 5-triazolyl, 2-thienyl, 3-thienyl, carbazolyl, 
benZimidazolyl, benzothienyl, benzofuranyl, indolyl, quino 
linyl, benzotriazolyl, benzothiazolyl, benzooxazolyl, benZ 
imidazolyl, isoquinolinyl, indazolyl, isoindolyl, acridinyl, 
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and benzoisoxazolyl. The term “heteroaralkyl” refers to an 
alkyl group substituted by a heteroaryl. The term “heteroary 
lalkoxy” refers to an alkoxy group substituted by a heteroaryl. 
An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the 
like), heteroaryl (including heteroaralkyl, heteroarylalkoxy 
and the like), or heterocycloalkyl (including heterocycle, het 
erocyclyl or heterocyclic and the like) group may contain one 
or more substituents. Suitable substituents on an unsaturated 
carbon atom of an aryl, heteroaryl, aralkyl or heteroaralkyl 
group are selected from halogen; haloalkyl; H; 4CF3; iR; 
40R; iSR; l,2-methylenedioxy; l,2-ethylenedioxy; pro 
tected OH (such as acyloxy); phenyl (Ph); Ph substituted with 
R; iO(Ph); 4Oi(Ph) substituted with R; iCH2(Ph); 
4CH2(Ph) substituted with R; iCH2CH2(Ph); 4CH2CH2 
(Ph) substituted with R; iNOZ; iCN; *N(R)2; *NRC(O) 
R; iNRC(O)N(R)2; *NRCOzR; *NRNRC(O)R; iNRi 
NRC(O)N(R)2; *NRNRCOZR; iC(O)C(O)R; 4C(O) 
CH2C(O)R; iCO2R; 4C(O)R; iC(O)N(R)2; 4OC(O)N 
(Rb; *S(O)2R; *SOzN(R)2; *S(O)R; *NRSOZMRL; 
*NRSOZR; %(:S)N<R)2; *C(:NH)*N(R)2; 
i(CH2)y NHC(O)R; i(CH2)yR; i(CH2)yNHC(O)NHR; 
i(CH2)yNHC(O)OR; i(CH2)yNHS(O)R; i(CH2)y 
NHSOZR; or i(CH2)yNHC(O)CH((V)ZiR)(R) wherein 
each R is independently selected from hydrogen, optionally 
substituted C1_6 aliphatic, an unsubstituted 5-6 membered 
heteroaryl or heterocyclic ring, phenyl (Ph), 40(Ph), or 
4CH2(Ph)iCH2(Ph), wherein y is 0-6; Z is 0-1; andV is a 
linker group. When R is C1_6 aliphatic, it may be substituted 
with one or more substituents selected from iNH2, iNH 
(C1_4 aliphatic), iN(C1_4 aliphatic)2, iS(O)(C1_4 aliphatic), 
iSO2(Cl_4 aliphatic), halogen, (Cl_4 aliphatic), iOH, 
40(C1_4 aliphatic), iNOZ, 4CN, iCO2H, 4C02(C1_4 
aliphatic), 40(halo C1_4 aliphatic), or -halo(C1_4 aliphatic); 
wherein each C 1_ 4 aliphatic is optionally. 
An aliphatic group, including alkyl, alkenyl, alkynyl or a 
non-aromatic heterocyclic ring may contain one or more sub 
stituents. Suitable substituents on a saturated carbon of an 
aliphatic group or of a non-aromatic heterocyclic ring are 
selected from those listed above for the unsaturated carbon of 
an aryl or heteroaryl group and the following: :0, :S, 
:NNHR, :NN(R)2, :Ni, :NNHC(O)R, :NNHCO2 
(alkyl), :NNHSO2(alkyl), or :NR, where each R is inde 
pendently selected from hydrogen or an optionally substi 
tuted C1_6 aliphatic. When R is C1_6 aliphatic, it may be 
substituted with one or more substituents selected from 
iNHz, 
iNH(Cl_4 aliphatic), iN(Cl_4 aliphatic)2, halogen, iOH, 
4Oi(Cl_4 aliphatic), iNOz, 4CN, 4C02H, 4C02(C1_4 
aliphatic), 40(halo C1_4 aliphatic), or -halo(C1_4 aliphatic); 
wherein each C1_4 aliphatic is optionally substituted. 
Substituents on a nitrogen of a non-aromatic heterocyclic 
ring are selected from iR, iN(R)2, 4C(O)R, iC(O)OR, 
4C(O)C(O)R, 4C(O)CH2C(O)R, iSOZR, iS02N(R)2, 
4C(:S)N(R)2, iC(:NH)iN(R)2 or iNRSOZR; 
wherein each R is independently selected from hydrogen, an 
optionally substituted C1_6 aliphatic, optionally substituted 
phenyl (Ph), optionally substituted iO(Ph), optionally sub 
stituted iCH2(Ph), optionally substituted 4CH2CH2(Ph), 
or an unsubstituted 5-6 membered heteroaryl or heterocyclic 
ring. When R is a C 16 aliphatic group or a phenyl ring, it may 
be substituted with one or more substituents selected from 
iNH2, iNH(C 1_ 4 aliphatic), iN(C1_4 aliphatic)2, halogen, 
i(Cl_4 aliphatic), 40H, iOi(Cl_4 aliphatic), iNOZ, 
4CN, 4CO2H, iCOZ(Cl_4 aliphatic), 40(halo C1_4 ali 
phatic) or -halo(Cl_4 aliphatic); wherein each C1_4 aliphatic is 
optionally substituted. 
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The term “linker group” or “linker” means an organic 
moiety that connects two parts of a compound. Linkers 
include alkylidene chain that is a saturated or unsaturated, 
straight or branched, C1_8 carbon chain which is optionally 
substituted, and wherein up to two non-adjacent saturated 
carbons of the chain are optionally replaced by R* wherein 
(0)4, 4S4, iSOi, iSOZi, iNRi, iSOZNRi, or 
iNRSOZi; wherein R is selected from hydrogen or option 
ally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl 
or heteroaryl, and preferably H or optionally substituted C1_4 
aliphatic. Optional substituents on the alkylidene chain are as 
described above for an aliphatic group. Alternatively, the 
linker group is R*. 
The term “treatment” refers to any treatment of a patho 
logic condition in a mammal, particularly a human, and 
includes: (i) preventing the pathologic condition from occur 
ring in a subject which may be predisposed to the condition 
but has not yet been diagnosed with the condition and, accord 
ingly, the treatment constitutes prophylactic treatment for the 
disease condition; (ii) inhibiting the pathologic condition, 
i.e., arresting its development; (iii) relieving the pathologic 
condition, i.e., causing regression of the pathologic condi 
tion; or (iv) relieving the conditions mediated by the patho 
logic condition. 
The term “therapeutically effective amount” refers to that 
amount of a compound of the invention that is suf?cient to 
effect treatment, as de?ned above, when administered to a 
mammal in need of such treatment. The therapeutically effec 
tive amount will vary depending upon the subject and disease 
condition being treated, the weight and age of the subject, the 
severity of the disease condition, the manner of administra 
tion and the like, which can readily be determined by one of 
ordinary skill in the art. 
The term “pharmaceutically acceptable salts” includes, but 
is not limited to, salts well known to those skilled in the art, for 
example, mono-salts (e.g. alkali metal and ammonium salts) 
and poly salts (e.g. di- or tri-salts) of the compounds of the 
invention. Pharmaceutically acceptable salts of compounds 
of formulas (I), (11), (III), or (IV) are where, for example, an 
exchangeable group, such as hydrogen in iOH, iNHi, or 
iP(:O)(OH)i, is replaced with a pharmaceutically 
acceptable cation (e.g. a sodium, potassium, or ammonium 
ion) and can be conveniently be prepared from a correspond 
ing compound of formula (I) by, for example, reaction with a 
suitable base. In cases where compounds are suf?ciently 
basic or acidic to form stable nontoxic acid or base salts, 
administration of the compounds as salts may be appropriate. 
Examples of pharmaceutically acceptable salts are organic 
acid addition salts formed with acids that form a physiologi 
cal acceptable anion, for example, tosylate, methane 
sulfonate, mesylate, acetate, citrate, malate, malonate, fuma 
rate, tartarate, succinate, benzoate, ascorbate, 
(x-ketoglutarate, and (x-glycerophosphate. Suitable inorganic 
salts may also be formed, including hydrochloride, sulfate, 
nitrate, bicarbonate, and carbonate salts. 
Pharmaceutically acceptable salts include quaternary 
ammonium salts formed with R'Y; where Y is selected from 
halogen, tosylate, methanesulfonate, benzenesulfonate, trif 
luoromethanesulfonate and the like; and R' is selected from 
an optionally substituted cycloalkyl, heterocycloalkyl, aryl or 
heteroaryl. 
Suitable acids include hydro?uoric acid, hydrochloric 
acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric 
acid, phosphoric acid, carbonic acid, boric acid, selenious 
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acid, hydrogen sul?de, phosphomolybdic acid, phosphorous 
acid, sulfurous acid, citric acid, maleic acid, D-malic acid, 
L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, meth 
anesulfonic acid, valeric acid, oleic acid, lauric acid, para 
toluenesulfonic acid, 1-naphthalensulfonic acid, 2-naphtha 
lensulfonic acid, phthalic acid, tartaric acid, L-malic acid, 
DL-malic acid, malonic acid, succinic acid, fumaric acid, 
glycolic acid, thioglycolic acid, glycine, sarcocine, sulfonic 
acid, nicotinic acid, picolinic acid, isonicotinic acid, benzoic 
acid and substituted benzoic acid where benzene ring bears 
one or more substituents. 
Pharmaceutically acceptable salts may be obtained using 
standard procedures well known in the art, for example, by 
reacting a suf?ciently basic compound such as an amine with 
a suitable acid affording a physiologically acceptable anion. 
Alkali metal (for example, sodium, potassium or lithium) or 
alkaline earth metal (for example, calcium) salts of carboxy 
lic acids can also be made. 
The term “prodrug” or “prodrugs” is used in its ordinary 
meaning in the art and means a compound of the invention 
that has at least one functional moiety masked or protected by 
another moiety that is designed to be cleaved under particular 
physiological conditions, leaving the deprotected or 
unmasked compound of the invention. The use of masking 
agents is common and well-known in the art, for example, 
masking charged groups such as phosphate or phosphonate 
groups. All such masking agents are suitable and can be used 
with the compounds of the invention. Various agents such as 
acyloxy alkyl esters are described by Srivasta et al., (1984 
Bioorganic Chemistry 12, 118-12), and by Freeman et al. 
(1997 Progress in Medicinal Chemistry 34:112-147) which 
are each incorporated in their entirety herein by reference; 
and 3-phthalidyl phosphonate esters are described by Dang 
Q., et al., (1999 Bioorganic & Med. Chem. Letters, 9:1505 
1510), which is incorporated in its entirety herein by refer 
ence. For example, and not by way of limitation, Srivasta et al. 
also describe acetoxymethyl, isobutryloxymethyl, and piv 
aloxymethyl as masking agents. Other suitable masking 
groups comprising pivaloxyalkyl, e.g., pivaloxymethyl, or a 
pivaloyloxy group as described by Farquhar D. et al., (1995 J. 
Med. Chem., 38:488-495) which is incorporated in its entirety 
herein by reference. Still other masking or protecting agents 
are described in US. Pat. Nos. 4,816,570 and 4,968,788 both 
of which are incorporated in their entirety herein by refer 
ence. Lipid prodrugs are also suitable for use with the com 
pounds of the invention. By non-limiting example, certain 
lipid prodrugs are described in Hostetler et al., (1997 Bio 
chem. Pharm. 53:1815-1822), and Hostetler et al., 1996 Anti 
viral Research 31 :59-67), both of which are incorporated in 
their entirety herein by reference. Additional examples of 
suitable prodrug technology is described in WO 90/00555; 
WO 96/39831; WO 03/095665A2; US. Pat. Nos. 5,411,947; 
5,463,092; 6,312,662; 6,716,825; and US. Published Patent 
Application Nos. 2003/0229225 and 2003/0225277 each of 
which is incorporated in their entirety herein by reference. 
Such prodrugs may also possess the ability to target the drug 
compound to a particular tissue within the patient, e.g., liver, 
as described by Erion et al., (2004 J. Am. Chem. Soc. 126: 
5154-5163; Erion et al., Am. Soc. Pharm. & Exper. Ther. DOI: 
10.1124/jept.104.75903 (2004); WO 01/18013 A1; US. Pat. 
No. 6,752,981), each of which is incorporated in their entirety 
herein by reference. By way of non-limiting example, other 
prodrugs suitable foruse with the compounds of the invention 
are described in WO 03/090690; and by Harris et al., (2002 
Antiviral Chem & Chemo. 12: 293-300; Knaggs et al., 2000 
Bioorganic & Med. Chem. Letters 10: 2075-2078) each of 
which is incorporated in their entirety herein by reference. 
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The term “drug-likeness” refers to the concept that drugs 
share speci?c molecular properties that distinguish them 
from other natural or synthetic chemicals. A drug-like mol 
ecule has properties such as optimal solubility to both water 
and fat, for example an orally administered drug must be 
absorbed through the intestinal lining, be carried in aqueous 
blood andpenetrate the lipid cellular membrane of the cell. To 
be suf?ciently soluble in aqueous media such as blood and 
intracellular ?uid, solubility in water can be estimated from 
the number of e.g. hydrogen bond donors compared to alkyl 
side-chains in the molecule. However, too many H-bond 
donors can lead to low fat solubility, so the drug may not be 
able to penetrate the cell wall ef?ciently. In addition, the 
drug-like molecule must be of a smaller molecular weight. A 
traditional method to evaluate drug-likeness is to check com 
pliance with Lipinski’s Rule of Five, which covers the num 
ber of hydrophilic groups, molecular weight and hydropho 
bicity. 
Detailed Description 
Acute myelogenous leukemia (AML) is a life-threatening 
disorder in which normal blood-formation (hematopoiesis) is 
subverted by malignant transformation of normal stem or 
Progenitor cells. Although an enormous amount of research 
has been conducted in the area of therapeutic agents forAML, 
the standard of care has not substantially changed in over 30 
years. Regimens based on a combination of cytarabine (ara 
C) and an anthracycline are still considered the best frontline 
option for most patients, despite the relatively poor long-term 
prognosis (5 year survival of approximately 20%) (Lowen 
berg et al., 1999). Thus, new options for treatment of AML are 
a high priority. Notably, clinical development of experimental 
therapeutics is very fast in AML, due to the poor prognosis 
and rapid disease progression for late stage patients. There 
fore, initial testing inAML not only affords the opportunity to 
evaluate leukemia stem cell (LSC) targeting, but also has the 
practical advantage of promoting rapid clinical advancement 
for promising new agents. 
Previously, the naturally-occurring (plant derived) com 
pound parthenolide (PTL) was investigated with respect to 
anti-leukemia properties. PTL was found to be highly effec 
tive for induction of cell death of primary human AML speci 
mens (Guzman et al., 2005). Importantly, at comparable 
doses, PTL shows little to no toxicity to normal hematopoi 
etic cells, suggesting that non-speci?c side effects should be 
relatively low. Furthermore, PTL was shown to be equally 
effective amongst all subpopulations found within primary 
AML specimens, including the so-called leukemia stem cell 
(LSC). Studies over the past decade have strongly implicated 
a relatively rare LSC population as the key driving force in 
both the genesis of AML, as well as relapse following con 
ventional therapy (Dick, 2005). Indeed, several laboratory 
based studies have demonstrated that LSC are resistant to 
both cytarabine and anthracyclines, and that drug regimens 
which more effectively eradicate LSC lead to improved out 
come (Costello et al., 2000; Ishikawa et al., 2007). Therefore, 
agents that can effectively target the LSC population are of 
particular interest for the treatment of AML patients. 
Although one focus has been on development of treatment 
for AML, PTL has demonstrated activity for virtually every 
form of cancer. Indeed, the basic properties of PTL in cancer 
were ?rst reported in 1973 (Wiedhopf et al., 1973), and now 
appear in over 100 publications. These studies have demon 
strated pre-clinical activity of PTL for cancers of the breast, 
lung, prostate, colon, blood, liver, kidney, pancreas, brain, 
and bone (Patel et al., 2000; Sweeney et al., 2004, 2005; 
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Yoshikawa et al., 2007; Oka et al., 2007; Parada-Turska et al., 
2007; Suvannasankha et al., 2008; Wang et al., 2009; Zhang et 
al., 2009). Thus, PTL not only eradicates LSC, but also bulk 
AML cells and many other types of cancer. 
Detailed SAR studies of PTL were performed to better 
understand the basic chemistry required to mediate anti-leu 
kemia activity. Studies indicated that the (x-methylene-y -lac 
tone moiety is critical for the function of PTL, as this structure 
is known to mediate Michael addition reactions (N eelakantan 
et al., 2009). In biological systems, the consequences of this 
reactivity are most prevalent for free thiols and cysteine resi 
dues. In addition, it was demonstrated that the epoxide ring is 
also quite important for PTL activity, since loss of the epoxide 
ring resulted in at least a 10-fold reduction in anti-leukemia 
activity; molecular modeling data suggests that the epoxide 
moiety may be a critical structural element in providing the 
active molecular conformation of PTL. Unfortunately, PTL is 
relatively water-insoluble and has poor bioavailability and 
drug-likeness. A series of PTL analogs was previously pre 
pared with the goal of creating a more therapeutically useful 
derivative (N eelakantan et al., 2009). The most promising 
candidate to arise from these studies was dimethylaminopar 
thenolide (DMAPT, LC-l, 2), which demonstrated nearly 
1000-fold greater water solubility than PTL when formulated 
as a fumarate salt. In addition, DMAPT retains virtually iden 
tical anti-leukemia properties as PTL, including the ability to 
selectively target LSCs. Pharmacological studies in rats and 
dogs demonstrated that DMAPT is 70% orally bioavailable, 
and well tolerated at doses resulting in serum concentrations 
of up to 10-fold excess of the biologically active concentra 
tion (Guzman et al., 2007b). Based on these ?ndings, 
DMAPT has advanced to phase 1 clinical trials, and is cur 
rently being evaluated in patients with advanced hematologic 
malignancies. DMAPT and certain PTL analogs are dis 
closed in US. Pat. Nos. 7,312,242 and 7,678,904, each of 
which is incorporated herein by reference. 
Despite the characterization of DMAPT, there is still sig 
ni?cant opportunity for further development of parthenolide 
based compounds. DMAPT has a relatively short in vivo 
half-life (approximately two hours) which may limit its activ 
ity. Moreover, the design of this molecule does not readily 
afford opportunities to develop tissue-targeting strategies due 
to stability problems associated with drug formulation. This 
is related to the ability of the drug to undergo reverse Michael 
deamination reactions to generate parthenolide. 
MMB (3) was identi?ed during the course of SAR studies 
based on parthenolide (PTL, 1). In performing such studies, 
one PTL analog that was synthesized via selenium oxide 
oxidation was a C 10 hydroxymethyl derivative. Notably, 
hydroxylation of the C10 methyl group of PTL resulted in the 
concomitant conversion of the geometry of the C9 -C 1 0 double 
bond from trans to cis. The resulting product, a hydroxym 
ethyl 1(10)-cis-parthenolide analog, has previously been 
reported as melampomagnolide B (MMB, 3). El-Feraly, 
1 984. 
MMB has been found to exhibit identical anti-leukemia 
activity compared to PTL, as shown in FIG. 2. In one embodi 
ment, the disclosure provides pharmaceutical compositions 
and methods of treating leukemia and other cancers with 
MMB. Unfortunately, like PTL, MMB does not possess good 
drug-like properties for oral administration, as determined by 
the Lipinsky’s “rule of ?ve”. Lipinski et al., Experimental and 
computational approaches to estimate solubility and perme 
ability in drug discovery and development settings. Adv. 
Drug. Deliv. Rev. 2313-25, 1997. 
MMB exhibits a C14-OH substituent, which provides 
opportunities for synthetic derivatization strategies. In one 















